The recommended starting dose of INLYTA® is 5 mg twice daily, taken orally, approximately 12 hours apart, with or without food.¹ INLYTA® is available in 1 mg and 5 mg dose strengths to help dose adjustment.¹

Dose increase or reduction is recommended based on individual safety and tolerability.

The dose of INLYTA® can be increased or decreased in the absence or presence of adverse reactions. If a patient tolerates the recommended starting dose of 5 mg twice daily with no adverse reactions greater than grade 2 for 2 consecutive weeks, you can step up to 7 mg twice daily, unless their blood pressure is greater than 150/90 mmHg or they’re taking antihypertensive treatment.¹ The same criteria can then be applied to further increase their dose of INLYTA® to a maximum of 10 mg twice daily.¹ Conversely, if adverse reactions develop, the dose of INLYTA® can be reduced to 3 mg twice daily and then to 2 mg twice daily if needed.¹ Managing some adverse reactions may need temporary or permanent discontinuation and/or dose reduction of Inlyta® therapy.¹

A short half-life could potentially lead to a relatively quick resolution of some adverse reactions following temporary treatment discontinuation.^1–3 

The half-life of INLYTA^® is between 2.5 and 6.1 hours. Based on the short half-life of Inlyta, steady state is expected within 2 to 3 days of the initial dose.¹

Once any adverse reactions subside, treatment with INLYTA^® can be restarted, if necessary at a reduced dose.^1,3 INLYTA^® should be permanently discontinued if adverse events do not resolve.¹